Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

SINGAPORE] Locally headquartered biotech firm KPB Biosciences has failed to set aside a court order for its assets to be ...

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

In 2023, sales from Novo Nordisk's GLP-1 diabetes therapies grew 52% year over year. Ozempic and a sibling treatment called Rybelsus are to thank for that growth.

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

Diabetes drug Ozempic, along with its sibling product Wegovy, has provided a massive tailwind for Novo Nordisk (NVO -1.39%) this year as people grab at weight loss options.